drugset / Trial / NCT01138657

Efficacy and Safety of Adalimumab in Patients With Active Uveitis

NCT01138657

Phase 3 Completed 239 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study comparing the safety and efficacy of adalimumab compared with placebo in patients with active uveitis.

Timeline

Start
2010-08
Primary completion
2014-07
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Background Prednisone Other / unclassified 60 mg Oral

Indications